One O-linked sugar can affect the coil-to-β structural transition of the prion peptide by Chen, Pei-Yeh et al.
One O-linked sugar can affect the coil-to- structural
transition of the prion peptide
Pei-Yeh Chen, Chun-Cheng Lin, Yin-Ting Chang, Su-Ching Lin, and Sunney I. Chan†
Institute of Chemistry, Academia Sinica, Taipei, 11529, Taiwan, Republic of China
Edited by Douglas C. Rees, California Institute of Technology, Pasadena, CA, and approved July 29, 2002 (received for review March 8, 2002)
It has been known that the structural transition from PrPC to PrPSc
leads to the prion formation. This putative conformational change
challenges the central dogma of the protein folding theory—‘‘one
sequence, one structure.’’ Generally, scientists believe that there
must be either a posttranslational modification or environmental
factors involved in this event. However, all of the efforts to solve
the mystery of the PrPC to PrPSc transition have ended in vain so far.
Here we provide evidence linking O-linked glycosylation to the
structural transition based on prion peptide studies. We find that
the O-linked -GalNAc at Ser-135 suppresses the formation of
amyloid fibril formation of the prion peptide at physiological salt
concentrations, whereas the peptide with the same sugar at
Ser-132 shows the opposite effect. Moreover, this effect is sugar
specific. Replacing -GalNAc with -GlcNAc does not yield the
same effect.
The prion protein (PrP, 254 aa for hamster PrP) has beenfound to be associated with the prion infectivity. The normal
product of the prion gene is expressed as a glycophosphatidyl
inositol-anchored glycoprotein on the outer cell membrane
(1–3). The solution NMR structure of recombinant syrian
hamster prion protein rPrP(90–231) was determined in 1997 (4).
The secondary structure consists of three -helices (144–153,
172–194, 200–227) interdispersed between two short -strands
(129–131, 161–163); the N terminus (90–111) is largely unstruc-
tured (Fig. 1). A posttranslational process that converts the
cellular prion protein (PrPC) to the abnormal, insoluble, patho-
genic isoform (PrPSc) has been implicated in the prion formation
during the development of prion diseases.
CD spectroscopy and Fourier transform infrared spectroscopy
studies have indicated that approximately half of the -helical
and coiled structure in PrPC is transformed into -sheet in PrPSc
(5). However, the thermodynamics of the -to- transition,
including the factors that influence it, remain unknown. PrPC has
a high turnover rate in vivo. This high turnover makes the
purification of PrPC extremely difficult (6). The low yield of
purified PrPC from animal brains or low level of expression in
mammalian cells as well as the insolubility of PrPSc have re-
mained a bottleneck in prion research. It has been difficult to
discern whether there are chemical modifications in PrPC that
are absent in PrPSc or vice versa. Although Edman sequencing
data suggest that the amino acid sequence of PrPSc is identical
with the translational product of the prion gene (7), we cannot
rule out the possibility of low levels of unidentified chemical
modifications in PrPC or PrPSc as the culprit of the medical
malady. To date, the search for differential modifications be-
tween PrPC and PrPSc has focused on the two N-linked glyco-
sylation sites at N181 and N197. However, based on the results
of tunicamycin treatment, an N-linked glycosylation inhibitor
(8), as well as experiments on the expression of unglycosylated
mutated prion protein in neuroblastoma cells (9), N-linked
glycans are no longer linked to the disease.
Animal experiments have also suggested that the so-called
‘‘species barriers’’ in the transmission of the prion diseases reside
in differences in the primary structure of the PrP between the
inoculum and the host, with prion propagation proceeding most
efficiently when the sequences of the two are identical. More-
over, Kaneko and coworkers (10, 11) have noted that structural
differences or changes in the peptide domain corresponding to
human prion sequence 90–144 alone are directly relevant to the
transmission of prion diseases. In light of these observations,
most of the structural studies on prion peptides have focused on
this region.
Spectroscopic studies indicate that the peptides derived from
this region can form -helical or -sheet structures in response
to variations in the solvent system. For example, the peptides
104–122, 129–141, and 109–141 can be induced to form -helical
structures in aqueous solution in the presence of helix-promoting
organic solvents like hexafluoroisopropanol, trif luoroethanol, or
detergents such as SDS and dodecyl phosphocholine. On the
other hand, the peptide 90–145 forms -structures when dis-
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Fig. 1. (A) The amino acid sequence of PrP (108–144). Two putative O-linked
glycosylation sites, Ser-132 and Ser-135, are underlined. The predicted
secondary-structure profile of PrPSc is also shown. (B) The solution structure of
recombinant PrP (sequence 125–228) (PDB ID code 1B10) is produced by using
the program MOLSCRIPT (31).-Strands and-helices are displayed in yellow and
red, respectively. Ser-132 and Ser-135 are shown in blue by space-filled
presentation.
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solved in aqueous solution at physiological salt concentrations,
or in 50% acetonitrile (12). In light of the unique capability of
this region of the prion protein toward -to- conversion, we
believe that this region plays a key role in the posttranslational
processes that induce PrPC to form PrPSc (13).
In contrast to the N-linked glycosylation, the possibility that an
O-linked sugar might be involved in the PrPC–PrPSc conversion
has not been discussed. This is because O-linked glycans have not
been detected in isolated PrPC or in PrPSc. There could be a
number of reasons for this. First, the purification of PrPC relies
on the use of monoclonal antibodies, which do not necessarily
catch all populations. Second, O-glycans are more vulnerable
toward degradation during hydrazinolysis in the glycan assay.
Third, the O-glycosylated form might exist as a minor population
and could be easily missed. The sequence 108–144 of prion
protein contains four putative -strands (S1, S2, S3, and S4) in
PrPSc (14). Within this sequence, there are two serines, Ser-132
and Ser-135, which could be glycosylated. Both residues are
available as potential O-glycosylated sites because they reside in
the exterior of PrPC (Fig. 1).
In this work, we have examined the effects of O-linked
-GalNAc, -GalNAc, and -GlcNAc at Ser-132 and Ser-135 on
the conformation and solution properties of the prion peptide
108–144.
Materials and Methods
Peptide Synthesis. The synthesized prion peptide 108–144, de-
noted PrP(108–144), was prepared by the batch fluorenylme-
thoxycarbonyl (fmoc)-polyamide method. The N-terminal end of
the peptide was acetylated and the C-terminal end amidated to
alleviate any electrostatic interactions involving the two ends.
To synthesize the glycosylated peptides, Fmoc-Ser(Ac3--
D-GalNHAc)-OH, Fmoc-Ser(Ac3--D-GlcNHAc)-OH and
Fmoc-Ser(Ac3--D-GalNHAc)-OH were used instead of Fmoc-
Ser(tBu)-OH. The peptide with an -GalNAc at Ser-132 and
Ser-135 were denoted S132--GalNAc and S135--GalNAc,
respectively. The peptide with a -GlcNAc at Ser-132 and
Ser-135 were denoted S132--GlcNAc and S135--GlcNAc,
respectively. The peptide with an unnatural -GalNAc at
Ser-135 was denoted S135--GalNAc. Fmoc-Ser(Ac3--D-
GalNHAc)-OH, Fmoc-Ser(Ac3--D-GlcNHAc)-OH and
Fmoc-Ser(Ac3--D-GalNHAc)-OH were prepared by modifi-
cation of literature procedures (15–18).
CD Spectroscopy. The peptides were dissolved in 20 mM NaOAc
with 140 mM NaCl (pH 3.7) and incubated at room temperature.
CD spectra were recorded in a * CD spectrometer (Applied
Photophysics, Surrey, U.K.). CD spectra were recorded in a
1-mm cell, between 190 and 250 nm, and at room temperature.
A scan interval of 1 nm with an integration of 200,000 points was
used. The spectrum of the same buffer was collected as a baseline
and subtracted automatically.
NMR Spectroscopy. All NMR spectra were recorded on a Bruker
AM 500 NMR spectrometer. For one-dimensional spectra,
peptides were dissolved in a buffer of 20 mM NaOAc-d3140 mM
NaCl to a final concentration of 0.88 mM. A 1100 volume of
sodium 3-(trimethylsilyl)-propionic-2, 2, 3, 3-d4 acid solution
(0.75% in D2O) was added as an internal reference. The pH
values were adjusted to 3.7 for higher solubility. Quoted pH
values were not corrected for the DH isotope effect. Samples
were incubated at room temperature. Their solution 1H NMR
spectra were recorded as a function of time at 298 K. For
two-dimensional spectra, more concentrated samples were pre-
pared (1 mM). Spectra were acquired with 2,000 data points in
direct dimension and 512 increments in indirect dimension.
80-ms mixing time in total correlated spectroscopy (TOCSY)
and 300-ms mixing time in NOESY were used. Data were
processed by XWINNMR software (Bruker, Billerica, MA). The
shifted square sine bell window functions in both dimensions
were applied for all spectra. The ANSIG program (version 3.3) was
used to assign the spectra (19).
Electron Microscopy (EM). The peptides were dissolved in 20 mM
NaOAc with 140 mM NaCl (pH 3.7 or 5). Except in the case of
S132--GalNAc, the peptide solutions were incubated at room
temperature in advance to promote the fibril formation. S132-
-GalNAc solution showed fibril structure under EM without
advanced incubation. Peptide negative staining was performed
on carbon-coated 300-mesh copper grids. Samples were ab-
sorbed for 1 min, stained with 2% uranyl acetate for another
minute, and, after drying, were viewed in a ZEISS 902 electron
microscope at 80 kV at standard magnification of 50,000.
Results
Effects of -GalNAc on Fibril Formation. Not unexpectedly, EM of
the PrP(108–144) revealed the formation of fibril structures
(Fig. 2). The EM observation is corroborated by the negative
ellipticity at 218 nm in the CD spectrum and a vibrational band
at 1,627 cm1 in the Fourier transform infrared spectrum,
indicating that the PrP(108–144) had undergone -structure
formation after 14-day incubation (data not shown). As ex-
pected, fibril formation was enhanced at increasing peptide
concentrations, indicating that the process is concentration
dependent (Fig. 3). The solubility of the peptide decreases with
the increase of the buffer pH from 3.0 to 6.0. To shorten the
incubation time, the experiments were performed at pH 3.7.
Surprisingly, the addition of an -GalNAc group at Ser-135
suppressed the fibril formation. No fibril structure can be found
under EM (Fig. 2). When the 1H NMR spectra of S135--
GalNAc are compared closely with those of PrP(108–144) (Fig.
4), the most striking observation is the significant reduction in
the signal intensity of the PrP(108–144) peptide, which becomes
increasingly apparent for long incubation times. The intensity
Fig. 2. EM pictures of prion peptides. (A) PrP (108–144) at pH 5. (B) S135--
GalNAc at pH 5. (C) S132--GalNAc at pH 3.7. (D) S135--GlcNAc at pH 3.7. The
bars represent 150 nm in length.
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decreased with the propagation of amyloid formation and the
concomitant reduction in the concentration of water-soluble or
monomeric peptide, whereas that of S135--GalNAc remained
the same. This result is consistent with irreversible aggregation
of the PrP(108–144) peptide with time. The kinetics of inter-
conversion between the water-soluble monomer and the aggre-
gate is apparently slow so that only the monomeric peptide is
observed in the high-resolution spectrum.
However, the inhibitory effect of -GalNAc appears to be
site-specific, because S132--GalNAc does not have the same
effect. In fact, the fibrillization of S132--GalNAc is even faster
than that of PrP(108–144) (Fig. 5). The addition of some fibril
of S132--GalNAc to a solution of PrP(108–144) quickly ini-
tiates the fibrillogenesis. The similar heterogeneous seeding-
effect is also noted for the other peptides (Fig. 6). Thus, the
polymerization could be either a heterogeneously or homoge-
neously seeded process. In any case, that -GalNAc at Ser-135
interrupts the fibril assembly, while the same glycosylation at
Ser-132 accelerates the process, is startling indeed.
Effects of -GlcNAc on Fibril Formation. The apparent opposite
effect of a single -GalNAc when introduced to different
Fig. 3. Concentration-dependent fibrillogenesis. Below the critical concen-
tration, no fibril is formed. When the monomer concentration is higher than
the critical concentration, the monomer nucleates and condenses to form
the fibril. The fibrillogenesis continues until the equilibrium is achieved
when the monomer concentration drops to or below the critical concentra-
tion. The length of time before fibril formation commences is called lag time.
Fig. 4. The one-dimensional NMR spectra of PrP(108–144) and S135--
GalNAc after different incubation times.
Fig. 5. The fibrillization time course as monitored by CD. Œ, 0.05 mM
S135--GalNAc;, 0.05 mM S135--GlcNAc;E, 0.05 mM PrP(108–144); , 0.075
mM S135--GlcNAc;}, 0.05 mM S132--GalNAc. On day 10, the sample for 0.05
mM S132--GalNAc had reached equilibrium.
Fig. 6. Heterogeneously seeded polymerization. E, 0.05 mM PrP(108–144);
F, on day 12, S132--GalNAc fibril was added as a seed to the solution of 0.05
mM PrP(108–144); {, 0.075 mM S135--GalNAc; ‚, 0.075 mM S135--GalNAc
 S135--GlcNAc fibril; ƒ, 0.075 mM S135--GalNAc  PrP(108–144) fibril; },
0.075 mM S135--GlcNAc;Œ, 0.075 mM S135--GlcNAc S132--GalNAc fibril;
, 0.075 mM S135--GlcNAc  PrP(108–144) fibril.
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positions suggests that the local conformation stability of this
region is important in the nucleation step. To verify whether
different sugar species can have the same effect, we synthesized
another analog peptide with a -GlcNAc at Ser-135 (S135--
GlcNAc). Like -GalNAc, -GlcNAc is a common sugar unit for
O-linked glycosylation. In contrast to S135--GalNAc, which
remained a random-coil structure even after 6 months, the CD
spectrum of S135--GlcNAc showed a strong negative ellipticity
at 218 nm after 2 weeks of incubation (Fig. 7). Time course
experiments indicate that the rate of fibril formation is as
follows: S132--GalNAc PrP(108–144) S135--GlcNAc
S135--GalNAc. These interesting contrasts suggest that the
effects of glycosylation on the structural transition and fibrilli-
zation are site-specific and sugar-specific.
Sugar Specificity. To gain more insights into the sugar specificity,
the peptide with a -GlcNAc at Ser-132, denoted S132--
GlcNAc, was also prepared. Similar to S135--GlcNAc, S132-
-GlcNAc did not appear to exhibit any dramatically different
behavior toward fibril formation compared with PrP(108–144)
(Fig. 8). It seems that -GalNAc has a greater effect on either
promoting or attenuating fibrillization, than -GlcNAc. The only
differences between -GalNAc and -GlcNAc are the orienta-
tion of the glycosidic bond and the hydroxyl group at C-4
(Scheme 1).
To ascertain whether or not the sugar configuration affects the
fibrillization, the peptide with a -GalNAc at Ser-135, denoted
S135--GalNAc, was synthesized. Surprisingly, S135--GalNAc
did not form any fibrils even after the peptide solution was
incubated for 4 weeks, the time course over which S135--
GlcNAc has already started fibrillization (Fig. 8). Although we
do not know for sure yet whether or not S135--GalNAc will ever
undergo fibrillization and behave like S135--GalNAc, it is clear
that the orientation of the hydroxyl group at C-4 is important in
affecting the process.
The Solution Structures of the Peptides. Although an -GalNAc
attached at Ser-135 dramatically affected the fibrillogenesis
process of the peptide, there was no evidence from the NMR of
these peptides that glycosylation affected their solution struc-
tures in a major way. For example, when the two-dimensional
NMR spectrum of S135-GalNAc was compared with that of PrP
(108–144), only the H of Ser-135 was downfield shifted by about
0.2 ppm because of the glycosylation. Except for the amide
hydrogens of Ser-135 and Arg-136, which also exhibited down-
field shifts of about 0.2 ppm, most of these amide protons were
not shifted significantly (data not shown). Similarly, spectral
changes were noted for the other glycosylated peptides only in
the vicinity of the glycosylation site.
Discussion
Although covalent attachment of the sugar moiety exerts only a
minor influence on the solution structure of the water-soluble
monomer prion peptide, glycosylation has a dramatic effect on
peptide fibrillogenesis, as we have shown in this study. The
structural perturbations induced by the glycosylation are pri-
marily local. Thus, the effects of the glycosylation relate to the
conformational properties of the peptides in solution (as op-
posed to their equilibrium structures in solution), specifically,
the accessibility of other structural forms to the peptide under
ambient conditions. Evidently, for fibrillization, the ensemble of
conformational states associated with the -structure must
become thermally accessible, or become sufficiently accessible
to populate these states to seed the nucleation of amyloid fibrils.
Alternatively, the barrier for transition between the random-coil
prion peptide and the -structure must be lowered to facilitate
the structural transition between the two forms (Fig. 9). Appar-
ently, adding an -GalNAc at Ser-132 stabilizes the -structure
relative to the random coil, rendering the structural conversion
from the random coil to the -structure kinetically more facile,
or thermodynamically more favorable, whereas adding the same
sugar at Ser-135 has the opposite effect. Prion peptides with
different glycosylations show different lag-times of amyloid
formation, indicating that glycosylation must affect the barriers
Fig. 7. Comparison of the fibrillization propensity between S135--GalNAc
and S135--GlcNAc. The CD spectra of these peptides in 20 mM NaOAc buffer
with 140 mM NaCl (pH 3.7) were recorded after different incubation times.
Solid line, 0.1 mM S135--GalNAc incubated for 6 months; dashed line, 0.075
mM S135--GlcNAc incubated for 2 weeks only.
Scheme 1. -GlcNAc (left) and -GalNAc (right) as linked to the side-chain of
a serine residue via the glycosidic bond.
Fig. 8. The effect of sugar configuration on fibrillization. The CD spectra of
0.05 mM peptides in 20 mM NaOAc buffer with 140 mM NaCl (pH 3.7) were
recorded after different incubation times. Black solid line, S135--GlcNAc
incubated for 4 weeks; red solid line, S135--GalNAc incubated for 4 weeks;
black dashed line, S132--GalNAc incubated for 2 weeks only; red dashed line,
0.05 mM S132--GlcNAc incubated for 4 weeks.
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of the nucleation processes that ultimately culminate in fibril-
logenesis as well.
Thus, glycosylation alters the kinetic equilibrium between the
water-soluble monomer (-helix conformation in the case of
prion protein, or random coil conformation in the case of prion
peptide) and the prion-induction form (-sheet conformation),
as well as the kinetics of the nucleation processes that lead to
fibrillogenesis. The stability and the solubility of the prion
protein or peptide species, as well as their resistance to proteases,
are critical to the kinetics of the nucleation process, as a critical
concentration must be reached before nucleation could occur.
The formation of these nucleation centers, which probably exist
only in minor amounts and are difficult to detect, is critical to the
initiation of the seeded polymerization. Fig. 10 depicts a non-
catalytic nucleated polymerization model (20–22) that might be
used to illustrate the nature of the seeded polymerization.
Amyloid formation might be promoted by the seeding effect of
a minor amount of nuclei. The nuclei might come from the local
increase in the protein concentration over the critical concen-
tration or the decrease of the critical concentration in response
to the cellular environmental change (homogeneous seeding).
The formation of these nuclei might be accelerated by the
aberrant glycosylation machinery, or introduced from an exter-
nal environment through transfection (heterogeneous seeding).
It has been suggested that prion propagation is facilitated by
homology within the central sequence of PrPC and PrPSc. The
transmission of prion diseases between species is often much less
efficient than transmission within the species. The requirements
for sequence similarity might offer clues for the species-barrier
during the disease transmission. In other words, in the case of
prion infection, the species barrier depends on the efficiency
difference between homogeneous seeding and heterogeneous
seeding.
Studies of transgenic mice indicate that a factor designated
‘‘protein X’’ appears to interact with PrPC and is involved in the
conversion of PrPC to PrPSc (23). Rudd and his coworkers (24)
have compared the glycan composition between PrPC and PrPSc.
They have found that PrPSc contains decreased levels of glycans
with bisecting sugars and increased levels of tri- and tetra-
antennary sugars, and have suggested that the glycosylation
machinery might be perturbed during the PrPC-PrPSc conversion
(24). Here we have shown that only one sugar unit can affect the
formation of amyloid fibril. This finding raises the question as to
whether glycosylation-related enzymes are the mysterious pro-
tein X that initiates the prion formation.
In this article, we report conformational effects on the prion
peptide induced by the covalent attachment of two monosac-
charides: GlcNAc and GalNAc. Although GalNAc shows a more
dramatic influence on the coil (or )-to- structural conversion
of the prion peptide, the effects associated with this sugar are
Fig. 9. The conformational energy diagrams of the prion peptides with and without glycosylation.
Fig. 10. A model for the noncatalytic seeded polymerization. This model
supposes that the various glycosylated forms have different ability to go
through the coil-to- (or -to-) structural transition and fibrillization. The
fibrillogenesis process can be homogeneously seeded, or heterogeneously
seeded by the nuclei provided from the external environment or formed
because of aberrant glycosylation.
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probably not physiological. In contrast, the fact that O-GlcNAc
glycosylation has been found in many proteins, including the tau
protein and the -amyloid precursor membrane protein related
to the neuron degenerative Alzheimer’s disease, emphasizes the
physiological significance of GlcNAc (25–28). O-linked GalNAc
generally occurs in mucin-type glycoproteins that contain re-
peating units of Ser, Thr, and Pro in short regions of the peptide
chain (29). Thus, we do not normally expect GalNAc to be
associated with the -to- conversion of the prion protein in vivo,
because there are only two Ser and one Pro in this polymorphic
region. However, when it does happen, the effects should be
dramatic, if not catastrophic, as we have demonstrated here. At
this juncture, it is not possible to rule out this possibility one way
or another, as our knowledge about O-glycosylation remains
pretty limited.
Recently, Peretz and coworkers (30) attempted to find a way
to prevent PrPC-PrPSc conversion by using various antibodies
recognizing different epitopes of PrPC. Their conclusions point
to the 132–140 domain of PrPC as closely related to the prion
propagation. Interestingly, this region overlaps with our O-
linked glycosylation sites. In the present study, we show that
glycosylation in this region can affect the thermodynamics of the
coil-to- (or -to-) structural conversion of the prion peptide.
This result might implicate or link the O-linked glycosylation
with prion formation.
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